Related Experiment Video

Updated: Jul 3, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Antithrombotic therapy in patients treated with oral anticoagulation undergoing coronary artery stenting. An expert

Andrea Rubboli1, Jonathan L Halperin, K E Juhani Airaksinen

  • 1Division of Cardiology, Cardiac Catheterization Laboratory, Maggiore Hospital, Bologna, Italy. andrearubboli@libero.it

Annals of Medicine
|July 9, 2008
PubMed

Insights

For patients with atrial fibrillation (AF) undergoing coronary stenting (PCI-S), triple therapy with warfarin, aspirin, and clopidogrel is recommended, despite increased bleeding risk. Warfarin plus aspirin alone is not effective.

Area of Science:

  • Cardiology
  • Pharmacology
  • Interventional Cardiology

Background:

  • Dual antiplatelet therapy (aspirin and clopidogrel) is standard after coronary stenting (PCI-S).
  • Optimal antithrombotic strategies for patients with atrial fibrillation (AF) requiring oral anticoagulation (OAC) post-PCI-S are not well-defined.
  • Atrial fibrillation is a common indication for OAC in this patient group.

Purpose of the Study:

  • To systematically review the safety and efficacy of antithrombotic strategies in patients with AF undergoing PCI-S who require OAC.
  • To evaluate current treatment practices and identify optimal therapeutic regimens.

Main Methods:

  • Systematic review of available evidence.
  • Analysis of antithrombotic strategies used in patients treated with OAC undergoing PCI-S.
  • Focus on patients with atrial fibrillation as the primary indication for OAC.

Main Results:

  • Triple therapy (warfarin, aspirin, and clopidogrel) was the most frequent and effective combination post-PCI-S.
  • Warfarin plus aspirin alone demonstrated insufficient early efficacy and is not recommended.
  • An increased risk of major bleeding is associated with triple therapy.

Conclusions:

  • Triple therapy with warfarin, aspirin, and clopidogrel is currently recommended for patients with AF undergoing PCI-S, balancing efficacy and bleeding risk.
  • Restrictive use of drug-eluting stents is advised due to prolonged antithrombotic therapy needs.
  • Further research is needed to evaluate warfarin plus clopidogrel (without aspirin) for potentially reduced bleeding risk while maintaining efficacy.

More Related Videos

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...